SELDI蛋白质芯片技术在肿瘤蛋白质组学研究中的应用-东南大学学报医学版

SELDI蛋白质芯片技术在肿瘤蛋白质组学研究中的应用

单位：东南大学基础医学院,病理学与病理生理学系,江苏,南京,210009

分类号：R730.45, R318.5

出版年·卷·期（页码）：2004·23·第五期（347-350）

摘要：

SELDI蛋白质芯片技术是结合色谱学/层析原理和SELDI-TOF-MS技术制成的新一代生物芯片,是目前肿瘤蛋白质组学研究的重要工具之一.它的优点是能洞察肿瘤细胞、组织和生物体蛋白质含量的细微变化,且能精确分析某一特定蛋白质的理化性质.作者就SELDI蛋白质芯片联合二维电泳、激光捕获显微切割等技术在肿瘤蛋白质组学研究中所应采取的策略,SELDI蛋白质芯片在肿瘤蛋白质组学研究中的临床应用如筛选肿瘤标志蛋白、预测肿瘤转移和预后等作一综述.

SELDI proteinchip technique, which combines the chromatography principle and SELDI、TOF、MS technique, is the newest biochip, and one of the important tools in the research of the tumors’ proteomics. It can identify the subtle changes of the proteinic contents in the tumor’s cells、tissues and bodies. Moreover, it can precisely analyse the chemical and physical qualities of a certain protein. This review retrospects the strategies in the research of tumors’ proteomic of the proteinchip when combined with other techniques,like 2、D PAGE and LCM, etc,as well as the clinical application of the SELDI proteinchip to the research of tumors’ proteomic such as identifying the tumors’ proteinic marks and forecasting the metastasis and prognoses.

参考文献：

[1] WASHINGER V C, CORDWELL S J, CERPA P. Progression with gene-product mapping of the mollicutes:Mycoplasma genitalium. 1995(7). doi:10.1002/elps.11501601185
[2] Eggeling F V, JUNKER K, FIEDLER W. Mass spectrometry meets chip technology:A new proteomic tool in cancer research?. 2001. doi:10.1002/1522-2683(200108)22:14&lt, 2898::AID-ELPS2898&gt, 3.0.CO, 2-A
[3] GASTORA F, CAZARES L H, CONYERS B. Profiling of Alzheimer's brain mitochondrial proteins using surface enchanced laser desorption/ionization(SELDI) mass spectrometry, 2002
[4] Rosty C, CHRISTA L, KUZDZAL S. Identification of hepatocarcinoma-intestine-pancreas/pancreatitis -associated proteinⅠ as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology, 2002
[5] Adam B L, QU Y, DAVIS J W. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. 2002
[6] Beher D, WRIGLEY J D J, OWENS A P. Generatiom of c-terminally truncated amyloid-beta peptides is dependent on gamma-secretase activity. 2002(3). doi:10.1046/j.1471-4159.2002.00985.x
[7] ZHUKOV T A, JOHNSON R, TOCKMAN M S. Discovery of distinct protein profiles specific for lung tumors and pre-malignant lung lesions by SELDI mass spectrometry. 2003
[8] Roboz J, MAL H, SUNG M. Protein profiles of serum in colon cancer by SEIDL-TOF mass spectrometry, 2002
[9] Petricoin E F, ARDEKANI A M, HITT B A. Comparison of protein profiles in plasma between early and late stage ovarian cancer patients in serum to identify ovarian cancer. 2002. doi:10.1016/S0140-6736(2)07746-2
[10] ARDEKANI A M, LIOTTA L A, PETRICOIN E F. Clinical potential of proteomics in the diagnosis of ovarian cancer, 2002
[11] Petricoin Ⅲ E F, ARDEKANI A M, HITT B A. Use of proteomic patterns in serum to identify ovarian cancer, 2002
[12] Li J, ZHANG Z, ROSENZWEIG J. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. 2002
[13] Paweletz C P, TROCK B, PENNANEN M. Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF:potential for new biomarkers to aid in the diagnosis of breast cancer, 2001(4)
[14] Adam B L, VLAHOU A, SEMMES O J. Proteomic approaches to biomarker discovery in prostate and bladder cancers, 2001
[15] DIAMOND D L, ZHANG Y, GAIGER A. Use of proteinchip array surface enhanced laser desorption/ionization time-of-flight mass spectrometry (seldi-tof ms) to identify thymosin beta-4, a differentially secreted protein from lymphoblastoid cell lines. 2003(7). doi:10.1016/S1044-0305(3)00265-4
[16] Wu W, TANG X, HU W. Identification and validation of metastasis -associated proteins in head and neck cancer cell lines by two-dimensional electrophoresis and mass spectrometry. 2002. doi:10.1023/A:1015515119300

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录